Sanofi's Lemtrada Shines in Extended Study

Sanofi’s (NYSE: SNY  ) multiple sclerosis drug Lemtrada showed strong results in the first year of an extended phase 3 study, reducing relapse rates in treated patients and improved disability outcomes, the company said this week.

The study results [file opens in PDF], released by Sanofi and subsidiary Genzyme, came as the European Medicines Agency and the FDA review Lemtrada for regulatory decisions expected later in 2013.

Sixty-seven percent of patients new to treatment and 55% of patients who had relapsed on prior therapy remained relapse-free a year into the extended study. More than 70% of each patient group showed improved or stable disability, while more than 80% of patients didn’t require a third round of treatment during the trial.

Lemtrada’s safety profile remained steady as no new risks emerged for patients on the drug; infections were the most common adverse events over the course of the extended study’s first year. 

link


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 11, 2013, at 12:19 PM, ikkyu2 wrote:

    If you want a pure play on Lemtrada, you can buy Genzyme Contingent Value Rights, GCVRZ. These are a kind of warrant which have value if Lemtrada meets certain sales targets.

Add your comment.

DocumentId: 2327880, ~/Articles/ArticleHandler.aspx, 7/22/2014 9:27:50 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement